-
Technology
-

The NHS Data Contract Has Become a Test of Britain's Technology Ambitions

By
Distilled Post Editorial Team

At a hospital bed meeting, nobody has much time to think about the software behind the figures on the screen. Managers want to know why patients are waiting for beds, why discharges are delayed and whether theatre capacity is being used properly. The answers increasingly depend on information brought together through the NHS Federated Data Platform (FDP), the system operated by American technology company Palantir since March 2024. For the people relying on it, the technology is becoming part of the machinery of everyday NHS operations. Who controls that machinery, and who gets to supply its next version, has now become a question of considerable political and commercial importance.

The Government has confirmed that Palantir's contract will end in March 2029, following a decision not to exercise the break clause that could have brought the arrangement to an earlier close. Health Minister James Frith announced a new procurement in November, arguing that the NHS needs continuity while a successor is developed. The decision gives the incumbent another two years, but it also sets a clear deadline for the industry. The next competition will determine who builds the platform's future and how much room British companies have to participate.

The commercial stakes are substantial. The existing contract has a maximum potential value of £330m over seven years, although that figure should not be mistaken for money already spent or guaranteed to the supplier. Palantir leads a consortium that includes Accenture, PwC, NECS and Carnall Farrar. Its original appointment followed a competitive procurement in 2023. Now a group of more than 20 British health technology businesses, organised through the Drystone Health AI Collaboration and led by Shane Tickell of Temple Black, is preparing to challenge the incumbent. Voror Health Technologies and Black Pear Software are among the companies associated with the initiative. Quantexa, the London-based analytics business, has also been linked to a possible renewed bid.

For these companies, the opportunity goes beyond winning a government contract. Britain has developed a considerable pool of health technology expertise, much of it in smaller firms that understand the practical difficulties of NHS operations. They have worked with trusts, clinical teams and local health systems, often developing products around problems that large international technology groups may struggle to understand in detail. Yet the ability to build useful software does not automatically translate into the financial strength, delivery capacity and procurement experience required to operate infrastructure across the health service.

That is where the competition becomes difficult. Palantir already has a working relationship with NHS organisations and years of implementation experience. Its Foundry software supports the integration and analysis of information that would otherwise remain scattered across separate systems. NHS England has argued that the platform is helping organisations improve operational planning and patient care. The Government, meanwhile, has defended the need to preserve continuity while preparing the next generation of the service.

The concerns surrounding the arrangement have never disappeared. Clinicians, campaigners and trade unions have questioned the involvement of a company whose wider business activities have generated considerable public controversy. Parliament has also heard concerns about the NHS becoming too dependent on a small number of overseas technology providers. Palantir maintains that NHS data remains under NHS control and that its contractual rights do not permit the company to commercialise patient information or use it to develop its own products. Those safeguards matter. They do not, however, settle every question about long-term control of the technology itself.

The distinction between data ownership and technological independence deserves much closer scrutiny. The Government has insisted that the NHS retains ownership of its data and intellectual property, while Palantir has told ministers that the necessary exit arrangements are in place. That is reassuring, but contractual assurances will need to survive the practical business of moving an enormous, interconnected system. A trust cannot simply switch platforms overnight. Its staff need working systems, historical information, documented processes and the ability to continue managing patients without disruption. The transition must demonstrate that these things can move between suppliers without becoming prohibitively expensive.

This is where the question of British ownership becomes more complicated. Ministers have indicated that the new competition will be open to international providers, while giving UK small and medium-sized enterprises an opportunity to participate. That is a sensible starting point for a competition in which technical ability and delivery experience must carry considerable weight. Yet the Government must explain how it intends to recognise domestic capability when assessing bids. A company incorporated in Britain, a business employing British engineers and an internationally owned company operating a substantial UK workforce are three different propositions. Treating them as interchangeable would obscure what the procurement is supposed to achieve.

There is also a danger in making nationality the principal measure of success. A British supplier could win the contract and still create the same dependency if its technology is proprietary, difficult to export and expensive to replace. Equally, an overseas company could provide a more open system with stronger guarantees over data governance and interoperability. The relevant test should be whether the NHS can retain control of its infrastructure, understand how its systems operate and move elsewhere when commercial or operational circumstances demand it.

The forthcoming procurement should therefore place particular emphasis on technical standards, portability and transparent exit arrangements. Trusts must have clear rights over the configurations, workflows and operational logic developed with public money. Any replacement platform should be capable of communicating with existing NHS systems without forcing hospitals into another expensive cycle of integration. These requirements need to be written into the contract from the outset, rather than negotiated when a future dispute arises.

The timing matters. The Government's 10 Year Health Plan places digital transformation at the centre of its ambitions for a more productive health service, including better information sharing and the development of a single patient record. Those ambitions will remain difficult to achieve if hospitals are tied to technology they cannot readily adapt. The FDP is already becoming part of how NHS organisations understand demand and manage resources. Its next iteration will influence how much freedom they have to change those processes.

For Britain's health technology industry, the competition will be an important indication of whether ministers genuinely intend to develop domestic expertise at scale. Smaller companies need a procurement structure that allows them to demonstrate their capabilities, including through partnerships, rather than one that effectively reserves the field for organisations with the deepest financial resources. The Government should also be realistic about the scale of the undertaking. Replacing a national platform requires sustained investment, technical assurance and support for NHS staff throughout the transition.

Palantir will enter the process with an established position and considerable experience of the existing system. Its competitors will have to show that they can match the operational requirements while offering a credible route towards greater flexibility. Neither political pressure nor a preference for British ownership can substitute for that evidence.

By March 2029, the NHS should be in a position to change supplier without surrendering the knowledge, investment and operational improvements accumulated along the way. That is the real test of this procurement. Britain may well find a domestic company capable of taking the contract. What matters more is whether the next platform gives the NHS something it has struggled to secure for years: genuine control over the technology on which its daily operations increasingly depend.